Heart failure (HF) is the end stage of most cardiovascular diseases. Increasing evidence indicates that serum parathyroid hormone (PTH) is significantly elevated in patients with HF. Experimental studies confirm that there is a significant interaction between PTH, angiotensin Ⅱ and aldosterone, which may be involved in the pathogenesis of HF. This article reviews the relationship between PTH and HF and the possible mechanisms involved in the pathogenesis of HF, in order to accumulate the data of PTH as a new marker and clinical intervention target of HF.